Tyrogenex Report issue

For profit Phase 1 Phase 2
Founded: West Palm Beach FL United States (2006)
Status: Defunct (2020)

Organization Overview

First Clinical Trial
2011
NCT01296581
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (4)

aflibercept (zaltrap) (1 trial)

bevacizumab (avastin) (1 trial)

ranibizumab (lucentis) (2 trials)

x-82 (4 trials)

Drugs in Phase 1 Trials (2)

docetaxel (taxotere) (1 trial)

fluorothymidine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Eye Diseases (Phase 2)

Macular Degeneration (Phase 2)

Neoplasms (Phase 1)

Retinal Degeneration (Phase 2)

Retinal Diseases (Phase 2)

Wet Macular Degeneration (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 6